Shanghai Innostar Biotechnology Past Earnings Performance

Past criteria checks 1/6

Shanghai Innostar Biotechnology has been growing earnings at an average annual rate of 24.5%, while the Life Sciences industry saw earnings growing at 17.2% annually. Revenues have been growing at an average rate of 24.8% per year. Shanghai Innostar Biotechnology's return on equity is 5.7%, and it has net margins of 13.1%.

Key information

24.5%

Earnings growth rate

16.4%

EPS growth rate

Life Sciences Industry Growth	26.8%
Revenue growth rate	24.8%
Return on equity	5.7%
Net Margin	13.1%
Last Earnings Update	30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Shanghai Innostar Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:688710 Revenue, expenses and earnings (CNY Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	1,122	147	172	50
30 Jun 24	1,117	176	181	58
31 Mar 24	1,078	185	181	58
31 Dec 23	1,038	194	181	58
30 Jun 23	969	204	94	27
31 Mar 23	916	169	134	38
31 Dec 22	863	135	173	50
31 Dec 21	582	95	123	27
31 Dec 20	334	49	68	19
31 Dec 19	245	36	57	12

Quality Earnings: 688710 has a high level of non-cash earnings.

Growing Profit Margin: 688710's current net profit margins (13.1%) are lower than last year (19.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 688710's earnings have grown significantly by 24.5% per year over the past 5 years.

Accelerating Growth: 688710's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 688710 had negative earnings growth (-26.3%) over the past year, making it difficult to compare to the Life Sciences industry average (-14.4%).

Return on Equity

High ROE: 688710's Return on Equity (5.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/19 12:49
End of Day Share Price	2024/12/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Innostar Biotechnology Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution